ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselNuclidium AG
Nuclidium AG Logo
Verified· 3 sources

Nuclidium AG

Summary

About the company

The core activity of Nuclidium AG is the development, manufacture and marketing of radiopharmaceutical products, in particular copper-based radiopharmaceuticals, for cancer diagnosis and therapy.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered4
Radiopharmaceutical oncology pipeline
Development of copper-based therapeutics and companion diagnostics for precision oncology, including clinical programmes against prostate cancer, metastatic breast cancer and neuroendocrine tumours.
Copper-based radiotheranostics platform (CuTrace™)
Proprietary platform for diagnostic and therapeutic copper-based radiopharmaceuticals with Cu-61 and Cu-67 radionuclides, targeted molecules and improved production and distribution.
Production and supply chain for radiopharmaceuticals
Set-up and operation of a production and supply network for copper-based radiopharmaceuticals with scalable manufacturing, reliable supply and distribution in Europe and North America.
Copper User’s Group
Network for isotope producers, clinicians, researchers and industry partners to exchange data, coordinate supply and promote the clinical use of Cu radiotheranostics.
Press

Media

May 29, 2026Media
NUCLIDIUM's Series B reaches CHF 105 million with latest extension
startupticker.ch
July 10, 2025Media
CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform
startupticker.ch

Knowledge

No knowledge articles yet

Once Nuclidium AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Nuclidium AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Nuclidium AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Nuclidium AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Bäumleingasse 18
4051 Basel

At a glance

Legal form
Corporation
UID
CHE-412.395.606
Founded
2018 · 8 years
Last commercial register change
June 11, 2026
Employees
21 to 50

Similar companies

TT
TOLREMO therapeutics AG
Basel
MP
Mepha Pharma AG
Basel
ST
Synendos Therapeutics AG
Basel
TT
TargImmune Therapeutics AG
Basel